|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further ROC analysis demonstrated that serum GP73 was comparable to serum ALT and AST in diagnosing the liver necroinflammation grade at <i>G</i> ≥ 2, but its diagnostic values for advanced fibrosis (<i>F</i> ≥ 3) and cirrhosis (<i>F</i> = 4) were limited when compared to APRI and FIB-4, and FIB-4 exhibited the best performance.
|
31636735 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The area under the receiver-operating curve (AUROC) of AFP, AFP/(Aspartate aminotransferase*Alanine aminotransferase) [AFP/(AST*ALT)] and AFP/WBC were compared between the HCC group and the control groups for the quantifying diagnostic efficacy.AUROCs of our novel index AFP/(AST*ALT) were up to 0.853 (95% confidence interval, CI 0.818-0.887, P < .001) and 0.825 (95% CI 0.782-0.868, P < .001), respectively, when differentiating HCC from non-HCC patients and from cirrhosis patients, which was superior to AFP and AFP/WBC.
|
31027143 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When samples were grouped according to the serum level of AKR1B10 (≥232.7pg/ml), serum AKR1B10 positively correlated to serum AFP (χ<sup>2</sup>=6.295, P=0.012), ALT (χ<sup>2</sup>=18.803, P=0.000), AST (χ<sup>2</sup>=33.421, P=0.000), tumor nodule number (χ<sup>2</sup>=6.777, P=0.009), cirrhosis (χ<sup>2</sup>=43.458, P=0.000), and tumor size (χ<sup>2</sup>=6.042, P=0.014) in the Chi-square test.
|
31495535 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cirrhosis development was significantly associated with abnormal AST, age ≥40 years, BMI ≥28 kg/m<sup>2</sup>, HCV GT1, platelet count <100 × 10<sup>9</sup>/L, and APRI ≥2 (multivariate Cox regression, P < 0.05).
|
31566575 |
2019 |
|
Liver Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correlations are analyzed among petroleum and liver cirrhosis mortality, fatty liver, alanine amino transferase (abbreviated as ALT), aspartate amino transferase (abbreviated as AST).
|
30296610 |
2018 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TnC and AST together were significantly better indicators of cirrhosis in patients with active HCV infection than other markers tested.
|
29330728 |
2018 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
One-hundred treatment-naive CHC patients were subjected to liver biopsy, TE-FibroScan, and eight serum biomarkers tests; AST/ALT ratio (AAR), AST to platelet ratio index (APRI), age-platelet index (AP index), fibrosis quotient (FibroQ), fibrosis 4 index (FIB-4), cirrhosis discriminant score (CDS), King score, and Goteborg University Cirrhosis Index (GUCI).
|
29630460 |
2018 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, higher serum ALT, AST levels and more common cirrhosis were observed in AIH-1 patients with T allele (CT/TT) than those with CC genotype.
|
28448618 |
2017 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared to baseline values, chronic hepatitis patients who progressed to cirrhosis exhibited declines in mean platelet counts (225.7-195.2 mm(3), p = 0.008-0.04) during the first 4 years of follow-up, while those who reverted to being inactive carriers had substantial reductions in mean levels of AST (83.5-27.2 u/l, p < 0.001-0.002) and ALT (100.2-29.2 u/l, p < 0.001-0.007).
|
26219830 |
2015 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Liver biopsy is only required to search for cirrhosis whenever there is hepatomegaly and/or serum ferritin >1000 ng/ml and/or elevated serum AST.
|
11099895 |
2000 |
|
Liver Cirrhosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decrease of hepatic cytosolic AST activity was statistically significant only in alcoholic patients without cirrhosis who had a normal cytosolic AST mRNA level, thus suggesting a contributory role of translational or posttranslational regulation.
|
1916663 |
1991 |